



HIV PREVENTION

SUMMIT 2021

VIRTUAL | 1 - 2 DECEMBER 2021

Program



Dear Colleagues,

Welcome to the **HIV Prevention Summit 2021!**

We are living a new and exciting era in the field of HIV prevention. There is now a diverse assortment of antiretroviral drugs and formulations that can effectively prevent HIV infection. These, coupled with novel modes of action and new devices, provide clinicians with a wider range of choices to prevent HIV acquisition than ever before.

This two-day summit will provide the most current information on HIV prevention, as well as advances developing in the field. State-of-the-art lectures will explore antiretroviral drugs for prevention, novel formulations, devices, implementation strategies, individual and community-based behavioral aspects of prevention, as well as insights into the vaccine landscape and prospects of monoclonal antibodies for HIV prevention.

The universal educational needs regarding existing and novel prevention approaches will be addressed in the truly global context of the HIV epidemic.

And there will be ample opportunities and time for Q&A and debates.

I look forward to (virtually) meeting you!

Sincerely,

Mauro Schechter



**Mauro Schechter,
MD, PhD**

Federal University of Rio
de Janeiro, Brazil

Program Director



General Information

Abstracts

Accepted abstracts are published in **Reviews in Antiviral Therapy & Infectious Diseases, Volume 2021_11**.

Certificate of Attendance

Certificates of attendance will be sent by e-mail after completion of the post-summit survey.

Feedback

Your feedback is very valuable to us and enables us to further improve this summit. After each session a short questionnaire will pop-up and we would like to ask you to take a minute to complete it. After the summit, a survey will be sent to you via email, with further questions on how this summit could be improved.

Networking

The Meeting Hub allows you to connect and communicate with other attendees. Once you have located an attendee you want to connect with, click the Connect button. Once the other attendee accepts your request, you can choose to interact by starting a live chat or live video call. You can also schedule a meeting at a later time, send messages and take notes. Contact information for all attendees you have connected with will be included when you export contacts.

Notes

You will be able to take notes during the virtual summit. Any notes that you take throughout the event can be exported by selecting the Export icon in the top right of the screen near your Profile image.

Social Media

We encourage you to post news and tweet about [#PreventionSummitHIV](#) to your social media accounts as often as you like during the summit. You can either post your own tweets to your followers using the hashtag [#PreventionSummitHIV](#) or retweet a message through the official [@Virology_Edu](#) account.

Poster sessions

During the virtual summit, all accepted posters are displayed in the Poster Gallery. The Poster Gallery is always open for you. During the live poster viewing session on Wednesday 1 December at 18.40 PM CET you can visit the posters and interact with the presenters - just like if it was a face-to-face meeting. Make sure to take this opportunity and learn more about their interesting findings.

Presentations and webcasts

ame Webcasts of the presentations along with the PDF presentations will be available on www.AcademicMedicalEducation.com three weeks after the summit. You will be able to watch the presentations on the virtual summit portal until three weeks after the summit.

Time Zones

Times are in Central European Time. If you need to convert the times to your timezone, this website might be of interest to you: www.worldtimebuddy.com

Virtual Summit Platform

OnAIR is the virtual summit platform being used for HIV Prevention Summit 2021. A video tutorial on how to use the Workshop Portal can be found [here](#).

Our Team



Rikke Puggaard-Rode
Project Manager
Rikke.Rode@amededu.com



Eva Vamvounaki
Junior Project Coordinator
Eva.Vamvounaki@amededu.com

Disclaimer: This summit aims to offer participants the opportunity to share information. Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this summit. Virology Education disclaim all liability for injuries or losses of whatever nature incurred by individuals attending the summit.



Organizing Committee



**K. Rivet Amico,
PhD,**
University of Michigan,
United States



**Donn Colby,
MD, MPH,**
U.S. Military HIV Research
Program (MHRP) / Center for
Applied Research on Men and
Community Health,
United States / Vietnam



Simon Collins,
HIV i-Base,
United Kingdom



**Kenneth H. Mayer,
MD**
The Fenway Institute,
United States



**Nyaradzo Mavis Mgodi,
MBChB, MMed,**
University of Zimbabwe /
University of California San
Francisco,
Zimbabwe



**Mauro Schechter,
MD, PhD,**
Federal University of Rio de
Janeiro,
Brazil



Mitchell Warren,
AVAC,
United States



The HIV Prevention Summit 2021, Utrecht, Netherlands, 01/12/2021-02/12/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 4 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

EACCME® credits

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form.



Wednesday, 1 December 2021

Times are in Central European Time (CET)

Day 1: Prevention Programs of Today / Delivering What We Have

Program Director: Mauro Schechter

Opening of the Summit

- 4:00 PM **Opening Words**
Mauro Schechter, MD, PhD
Federal University of Rio de Janeiro, Brazil
- 4:05 PM **WHO Perspective on HIV Prevention - What Are the Gaps**
Rachel Baggaley, MBBS, MSc
WHO, Switzerland

Session 1 PrEP and PEP

Chairs: Mauro Schechter & Nyaradzo Mavis Mgodl

- 4:20 PM **Overview of Clinical Data on the Safety and Efficacy of Antiretroviral Drugs for HIV Prevention**
Roy M. Gulick, MD, MPH
Weill Cornell Medicine, United States
- 4:42 PM **Whatever Happened with PEP?**
Fiona Cresswell, PhD, MBChB, BSc, DTM&H, PGCert Epi, DipGUM, DFSRH
Brighton and Sussex Medical School, United Kingdom
- 5:00 PM Persistence on F/TAF versus F/TDF for HIV Pre-Exposure Prophylaxis: A Real-World Evidence Analysis in the United States
Corie Cruz-Beniasians, United States #1
- 5:05 PM **Roundtable Discussion**

5:25 PM Virtual Coffee Break - Time to Network

Session 2 PrEP Delivery Models

Chairs: K. Rivet Amico & Kenneth Mayer

- 5:35 PM **Why Don't Prescribers Prescribe?**
Douglas Krakower, MD
Beth Israel Deaconess Medical Center, The Fenway Institute, Harvard Medical School, United States
- 5:45 PM **Successes to Access PrEP and PEP: End-User Perspective**
Gcobisa Madlolo
AfnHi Youth Cohort, South Africa
- 5:55 PM **Successful Models of PrEP Implementation**
François Venter, MD, FCP, PhD
Divisional Head at Ezintsha, Sub-division of Wits RHI, Wits University, South Africa
- 6:05 PM Socio-Demographics of Individuals Initiated on HIV Pre-Exposure Prophylaxis (PrEP) in Nigeria
Augustine Idemudia, Nigeria #2
- 6:13 PM Community PrEP Service Delivery for Female Sex Workers in Ghana
Guro Lundby Sorensen, Ghana #3
- 6:20 PM **Roundtable Discussion**

6:40 PM **Poster Viewing Session**

7:10 PM End of Day 1



Thursday, 2 December 2021

Times are in Central European Time (CET)

Day 2: Prevention Programs of Tomorrow / Developing What We Still Need			
<i>Program Director: Mauro Schechter</i>			
4:00 PM	Opening of Day 2 Mauro Schechter, MD, PhD Federal University of Rio de Janeiro, Brazil		
Session 3 PrEP and PEP: Future Prospects <i>Chairs: Elizabeth Anne Bukusi & Nyaradzo Mavis Mgodli</i>			
4:05 PM	The Prevention Pipeline and Clinical Trial Design for PrEP Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD Desmond Tutu Health Foundation / University of Cape Town (UCT), South Africa		
4:20 PM	Novel Drug Delivery Systems on the Horizon Charles Flexner, MD Johns Hopkins University School of Medicine, United States		
4:40 PM	Q&A		
4:50 PM	Virtual Coffee Break - Time to Network		
Session 4 Abstract-Driven Session <i>Chairs: Simon Collins & Donn Colby</i>			
5:00 PM	Uptake of HIV Post-Exposure Prophylaxis, Completion Rates and Self-Reported Reasons for Non-Completion among Health Care Workers at Mbarara Regional Referral Hospital	Musiime Muzoora Dan, Uganda	#4
5:07 PM	Non-Occupational Post-Exposure Prophylaxis, Post-Violence Care and Ongoing HIV Risk in Kampala Uganda: Missed Opportunities for HIV Prevention through Pre-Exposure Prophylaxis and Other Interventions	Lisa Mills, Uganda	#5 & #6
5:18 PM	Intimate Partner Violence and Gender-Based Violence Among People Living with HIV in Southern Nigeria	Chika Okafor, Nigeria	#7
5:25 PM	Roundtable Discussion		
5:45 PM	Virtual Coffee Break - Time to Network		
Session 5 What Is the Future for Vaccines and Monoclonal Antibodies? <i>Chairs: Mitchell Warren & Mauro Schechter</i>			
5:55 PM	Antibody Mediated Prevention of HIV Myron Cohen, MD Institute for Global Health & Infectious Diseases, United States		
6:12 PM	State-of-the-Art and Future Prospects for HIV Vaccines Glenda E. Gray, MBBCh, FCPaed (SA), DSc South African Medical Research Council (SAMRC), South Africa		
6:30 PM	Roundtable Discussion		
Closing			
6:50 PM	Summary and Closure of the Summit Mauro Schechter, MD, PhD Federal University of Rio de Janeiro, Brazil		
7:00 PM	End of the Summit		



Faculty



ORGANIZING COMMITTEE

**K. RIVET AMICO,
PHD**

University of Michigan,
United States

K Rivet Amico, PhD, is an associate professor in the Department of Health Behavior Health Education at the University of Michigan's School of Public Health. She is a psychologist by training and a social-behavioral scientist with interests in the development, evaluation, and implementation of HIV treatment and prevention programs focused on health and wellbeing.

For over two decades, Dr. Amico has actively contributed to research, contextualizing experiences living with HIV and HIV prevention in the social and structural environments in which people navigate care and self-care. She has worked with adult and adolescent populations, as well as expecting and breastfeeding women, domestically in the US and internationally. She has developed and co-developed a number of brief intervention protocols, models/frameworks, and approaches to optimize person-facing care in the context of clinical trials and the roll-out of biomedical prevention products.

Dr. Amico is the chair of the Social Behavioral Science Core for the IMPAACT Network, leads the Social Behavioral Science Division for the Mid-West Capacity Building Assistance (CBA) Provider Network, is active in the ATN, and collaborates with service providers in the Michigan area.

Potential conflict of interest:
Gilead Sciences



INVITED SPEAKER

**RACHEL BAGGALEY,
MBBS, MSc**

World Health Organization,
Switzerland

Dr Rachel Baggaley is the team lead for testing, prevention, and populations in the Global HIV, Hepatitis and STI programmes at World Health Organization in Geneva.

This work includes supporting global normative guidance on HIV prevention (including PrEP, VMMC, vaccines, bNABs and other new prevention products), services for key populations, men and AGYW, SRH linkages and HIV testing, including HIV self-testing and partner testing services, and considering how these can be implemented strategically, safely and acceptably.

Before working for WHO, she worked on HIV in all regions with a focus on post-conflict countries and fragile states and worked on community-based programs for key populations.

No potential conflict of interest



INVITED SPEAKER

LINDA-GAIL BEKKER,
MBChB, DTMH,
DCH, FCP(SA), PhD

Desmond Tutu Health
Foundation / University of
Cape Town (UCT),
South Africa

Prof. Linda-Gail Bekker is the Director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, University of Cape Town and Chief Research Officer of the Desmond Tutu Health Foundation. She is a physician scientist and infectious disease specialist. Her research interests include programmatic and action research around antiretroviral roll out and TB integration, prevention of HIV in women, youth and MSM.

Prof. Bekker has also recently been involved in a number of COVID-19 vaccine trials and co-leads the Sisonke Phase 3B study which has seen the vaccination of 500 000 health care workers in South Africa. She has led numerous investigator-driven studies in HIV treatment, prevention and tuberculosis.

She is a past president of the International AIDS Society and served as the International Co-Chair of the 9th IAS Conference and 22nd International AIDS Conference and Co-Chaired the Research 4 Prevention Conference that was held in January 2021.

No potential conflict of interest



SESSION CHAIR

ELIZABETH ANNE BUKUSI,
MBChB, M.MED
(ObGYN), MPH, PhD,
PGD (RESEARCH ETH-
ICS), MBE (BIOETHICS),
CIP

Kenya Medical Research
Institute,
Kenya

Professor Elizabeth Anne Bukusi (ObGyn), MPH, PhD, PGD (Research Ethics), Masters in Bioethics, Fellow of the African Academy of Sciences, earned her general medical degree and Masters in Obstetrics and Gynecology degree from the University of Nairobi. She then earned a certificate in international health, MPH and a PhD from the University of Washington's Department of Epidemiology; a post graduate diploma in Research Ethics from the University of Cape Town and a Masters in Bioethics from Centre for Bioethics and Culture at the Sind Institute of Urology and Transplantation in Karachi. She is a certified IRB Professional. She is a Senior Principal Clinical Research Scientist at the Kenya Medical Research Institute (KEMRI), a Research Professor at the University of Washington (Departments of Obstetrics and Gynecology and Global health), an honorary lecturer at Aga Khan University in Nairobi And Maseno University (Department of Obstetrics and Gynecology) and Volunteer Clinical faculty – Professor at the University of California San Francisco (Department of Obstetrics, Gynecology & Reproductive Sciences).

Prof. Bukusi, in collaboration with Dr. Craig Cohen at UCSF, established the KEMRI Research Care and Training Program in 1995. In addition to her substantial experience in conducting socio-behavioral and biomedical research and providing HIV care, mentoring and training health care and research personnel to enhance local and international capacity, she has a strong interest in research and clinical ethics and the development of systems and structures for regulation of research at KEMRI and in the country. She is the chairperson of the National Bioethics Society of Kenya, (BSK), a multidisciplinary, non-political, non-discriminatory, and not-for-profit organization with a primary objective to promoting high ethical standards in bio-medical research, medicine and health care in Kenya. She is a board member of AVAC, Chaired the WHO HRP Alliance (capacity building for RH research), and is a trustee for the HIV Trust, and an Elected Fellow of the African Academy of Sciences (FAAS).

No potential conflict of interest



INVITED SPEAKER

MYRON COHEN, MD, BS

University of North Carolina
at Chapel Hill,
United States

Myron S. Cohen is the Yeargan-Bate Eminent Professor of Medicine, Microbiology and Immunology and Epidemiology at the University of North Carolina at Chapel Hill.

Dr. Cohen received his BS degree, Magna Cum Laude, from the University of Illinois, Champaign-Urbana. He received an MD degree from Rush Medical College, Chicago Illinois. He completed training in internal medicine at the University of Michigan, and training in infectious diseases at Yale University.

Dr. Cohen is a Fellow of the American College of Physicians and the Infectious Disease Society of America, and a member of the National Academy of Medicine, the American Society of Clinical Investigation and the American Association of Physicians. Dr. Cohen serves as the Director of the UNC Division of Infectious Disease and the UNC Institute for Global Health and Infectious Disease, and as Associate Vice Chancellor for Global Health. Dr. Cohen serves as the co-principal investigator of the NIH HIV Prevention Trials Network (HPTN).

Dr. Cohen is the author of more than 600 publications and one book. He has written extensively about the prevention of HIV infection and COVID-19. Much of Dr. Cohen's research has been conducted over the past three decades in resource constrained countries, especially in Malawi and in the People's Republic of China.

Dr. Cohen received the Distinguished Alumnus Award from Rush Medical College in 2000. He received the Distinguished Career Award for lifetime achievement in STD/HIV research from the American Sexually Transmitted Diseases Association in 2005. In 2008 Dr. Cohen received the O. Max Gardner Award, the highest honor in the University of North Carolina System. In 2013 Dr. Cohen received the Smadel Award from the Infectious Disease Society in recognition of his work in public health. Also in 2013, Dr. Cohen received the Award for Science from the State of North Carolina, its highest civilian honor

Potential conflict of interest:
Lineage Logistics



ORGANIZING COMMITTEE

DONN COLBY, MD, MPH

U.S. Military HIV Research
Program (MHRP) / Center for
Applied Research on Men
and Community Health,
United States / Vietnam

Dr. Donn Colby is a Research Physician at the U.S. Military HIV Research Program (MHRP). Based in Seattle, WA, he supervises collaborative studies with Joint Base Lewis-McChord (JBLM) in Washington State and contributes to clinical protocols implemented in Asia. Prior to joining MHRP in 2019, he was co-investigator on the RV254 trial of acute HIV infection at the Thai Red Cross AIDS Research Centre in Bangkok, Thailand.

Dr. Colby received his B.A. in Biology at Johns Hopkins University and his M.D. at the State University of New York at Stony Brook. He did his internal medicine residency training and Masters in Public Health at the University of Washington in Seattle.

Dr. Colby's research interests include the epidemiology of HIV in Southeast Asia, clinical outcomes among people living with HIV, the implementation of preexposure prophylaxis (PrEP), and clinical trials aiming to cure HIV infection.

Potential conflict of interest:
Gilead Sciences



ORGANIZING COMMITTEE

SIMON COLLINS

HIV i-Base,
United Kingdom

Simon Collins is an HIV positive treatment advocate at i-Base.info which he co-founded in April 2000.

i-Base supports HIV positive people to take an active role in their own health care. For many years he has produced and updated a series of non-technical treatment guides and edits a monthly technical review called HIV Treatment Bulletin (HTB).

Other i-Base services include a treatment information service that answers individual questions by phone, email and online.

Working with Community Advisory Boards he has developed close working relationships with numerous research groups. This included being a community representative on the PARTNER and START studies and the ongoing INSIGHT, RIO and EHVA studies.

In addition to i-Base publications he is a contributing author to many published papers, guidelines and conference presentations.

No potential conflict of interest



INVITED SPEAKER

FIONA CRESSWELL, PHD, MBChB, BSc, DTM&H, PGCERT EPI, DIPGUM, DFSRH

Brighton and Sussex Medical
School,
United Kingdom

I am a UK-trained Physician with expertise in HIV Medicine, Sexual Health and Tropical Medicine. I practice medicine at the University Hospital Sussex in the UK and hold an Academic Clinical Lectureship at Brighton and Sussex Medical School.

The main focus of my research is improving HIV treatment in sub-Saharan Africa and reducing mortality from advanced HIV disease. In 2016 I joined the brain infections research group at the Infectious Diseases Institute, Kampala, Uganda, and began a Wellcome-funded Clinical PhD Fellowship through the London School of Hygiene and Tropical Medicine. My PhD research is focused on HIV-related tuberculous meningitis (TBM). I conducted a phase II trial of high-dose rifampicin in TB meningitis and showed that it is safe to increase the dose of rifampicin by 3.5-fold in HIV-associated TBM. I continue to investigate novel diagnostics for meningitis and tuberculosis. I am part of the Harvest international consortium conducting a multi-country phase III trial investigating high dose rifampicin in TB meningitis. I am also interested in injectable antiretroviral therapy and am site principal investigator for CARES study – a phase III clinical trial investigating injectable cabotegravir and rilpivirine in Africa.

I chaired the 2021 British Association of Sexual Health and HIV national guideline on HIV post-exposure prophylaxis (PEP) which covers both sexual and occupational exposures. In 2010, I completed the DTM&H at Liverpool School of Tropical Medicine before working in a rural hospital in Tanzania, where I subsequently served as a Trustee for 6 years, overseeing >30 volunteer doctors, nurses, midwives to facilitate local capacity building. I have also enjoyed serving as an expedition medic with the BBC and tutoring on the East African DTM&H since its inception in 2011.

No potential conflict of interest



INVITED SPEAKER
**CHARLES FLEXNER,
 MD**

Harvard T.H. Chan School of Public Health, United States

Charles W. Flexner is Professor of Medicine in the Divisions of Clinical Pharmacology and Infectious Diseases, and Professor of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine. He is also Professor of International Health at the Bloomberg School of Public Health. Dr. Flexner is an expert on the basic and clinical pharmacology of drugs for HIV/AIDS and related infections, including viral hepatitis and tuberculosis. His scientific contributions include work on the important roles of pharmacokinetic enhancement, medication adherence, and dosing frequency in the long-term management of HIV/AIDS. He has published extensively on anti-infective drug transport and metabolism, and metabolic drug interactions.

His current research includes the discovery and development of new molecules and formulations for long-acting parenteral administration for treatment and prevention of HIV infection.

He directs the Long Acting/Extended Release Antiretroviral Research Resource Program (LEAP; www.longactinghiv.org), and the Johns Hopkins Baltimore-India Clinical Trials Unit. He is a member of the editorial board of 11 scientific journals. He is a consultant to the Bill and Melinda Gates Foundation and the Clinton Health Access Initiative, and serves on the WHO Clinical Guidelines Development Group for Treatment and Prevention of HIV in Adults, Adolescents, and Children.

Potential conflict of interest:

Merck, Mylan, ViiV Healthcare, Gilead Sciences



INVITED SPEAKER
**GLEND A. E. GRAY,
 MBBCH, FCPAEDS
 (SA), DSc**

South African Medical Research Council (SAMRC), South Africa

An NRF A1 rated scientist, CEO and President of the South African Medical Research Council (SAMRC), Professor Glenda Gray is a qualified paediatrician and co-founder of the internationally recognised Perinatal HIV Research Unit in Soweto, South Africa. Prior to her appointment at the SAMRC, she was the Executive Director of the Perinatal HIV Research Unit, an affiliate of Wits University.

Glenda's global profile includes a role as Co-PI of the HIV Vaccine Trials Network (HVTN), a transnational collaboration for the development of HIV/AIDS prevention vaccines. She is also Director of International Programmes for HVTN and Chairperson of the Board of the Global Alliance for Chronic Diseases, and a member of the Institute of Medicine of the National Academies, USA.

She received South Africa's highest honour - the Order of Mapungubwe - for her pioneering research in PMTCT. Other prestigious accolades include the Nelson Mandela Health and Human Rights Award for significant contributions in the field of mother-to-child transmission of HIV. Selected as one of Time's 100 Most Influential People in the World, Glenda is a recognised leader in her field. Her qualifications include an MBBCH, FCPaedS (SA), DSc (honoris causa SFU), DSc (honoris causa SUN), LL.D (Rhodes).

No potential conflict of interest



INVITED SPEAKER

**Roy M. GULICK,
MD, MPH**

Weill Cornell Medicine / New
York Presbyterian Hospital,
United States

Dr. Gulick is Rochelle Belfer Professor in Medicine and Chief of the Division of Infectious Diseases at Weill Cornell Medicine, and Attending Physician at the New York Presbyterian Hospital in New York City. He is board-certified in internal medicine and infectious diseases.

Dr. Gulick's research interests include designing, conducting, and analyzing clinical trials to refine antiretroviral therapy strategies for HIV treatment and prevention and assess antiretroviral agents with new mechanisms of action. He currently serves as Principal Investigator of the Cornell-New Jersey HIV Clinical Trials Unit of the AIDS Clinical Trials Group (ACTG) and the HIV Prevention Trials Network (HPTN), sponsored by the U.S. National Institutes of Health.

He also serves as the Co-Chair of the U.S. Department of Health and Human Services (DHHS) Panel on Clinical Practices for Treatment of HIV Infection, a Board Member of the International Antiviral Society-USA, and previously served as a Member and as Chair of the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) and as a Member and as Chair of the NIH Office of AIDS Research Advisory Committee (OARAC). He most recently serves as the Co-Chair of the NIH COVID-19 Treatment Guidelines Panel. He is a Member of the American Society of Clinical Investigation, the Association of American Physicians, the International AIDS Society, and the Infectious Diseases Society of America, and has presented at national and international meetings and published widely.

No potential conflict of interest



INVITED SPEAKER

**DOUGLAS KRAKOWER,
MD**

Beth Israel Deaconess
Medical Center, The Fenway
Institute, Harvard Medical
School,
United States

Dr. Douglas Krakower is Faculty in the Division of Infectious Diseases at Beth Israel Deaconess Medical Center, Research Scientist at The Fenway Institute, and Associate Professor of Medicine at Harvard Medical School.

His research focuses on ways to optimize HIV prevention in healthcare and community settings with a focus on implementing HIV preexposure prophylaxis (PrEP). His clinical practice encompasses general infectious diseases and HIV treatment and prevention.

Potential conflict of interest:

Merck; grant to my institution to study PrEP & personal funds for authoring medical education content on PrEP for UptoDate Inc.



INVITED SPEAKER

GCOBISA MADLOLO

AfNHi Youth Cohort,
South Africa

A PrEP champion, an award-winning PrEP activist who won the 2018 Omololu Falobi Award for excellence in HIV prevention research at the HIV R4P 2018.

An SRHR advocate, a writer, a fresh, inspiring, and powerful voice for young women in her native South Africa and beyond.

Potential conflict of interest:

Ndemba Technologies



ORGANIZING COMMITTEE

KENNETH MAYER, MD

The Fenway Institute,
United States

Dr. Mayer trained in Internal Medicine at Beth Israel Hospital and in Infectious Diseases and Molecular Epidemiology at Brigham and Women's Hospital. As the founding Medical Research Director of Fenway Health, he created a community health research program that has developed an international reputation for its capability to conduct community-based research.

He is currently a Professor of Medicine at Harvard Medical School, a Professor in Global Health and Population at the Harvard TC Chan School of Public Health, and Attending Physician and Director of HIV Prevention Research at Beth Israel Deaconess Hospital. Starting in 1994, he has been a site Principal Investigator of NIH-funded clinical trials units, focusing on bio-behavioral HIV prevention research, and is a member of the scientific leadership of HPTN.

He has co-authored more than 1000 peer-reviewed publications, co-authored the first text on AIDS for the general public and has co-edited 5 academic texts. He has served on the national boards of amfAR, HIVMA, and GLMA, was a member of the CDC/HRSA HIV/AIDS Advisory Committee, and was a member of the Governing Council of the International AIDS Society. He is an Editor-in-Chief of the Journal of the International AIDS Society, and serves on the PEPFAR Scientific Advisory Board.

Potential conflict of interest:

Gilead Sciences, ViiV, Merck



PROGRAM DIRECTOR
MAURO SCHECHTER,
MD, PhD

Federal University of Rio de Janeiro, Brazil

Mauro Schechter, MD, PhD, is professor of Infectious Diseases at the Department of Preventive Medicine of the Federal University of Rio de Janeiro, Brazil. He is also Adjunct Professor of Epidemiology at the Graduate School of Public Health, University of Pittsburgh, and Associate in the Department of International Health, Bloomberg School of Hygiene and Public Health, Johns Hopkins University.

He serves or has served on numerous Advisory Boards and Blue-Ribbon Panels, including the AIDS Clinical Trials Group (ACTG) Executive and Scientific Agenda Steering Committees, the Scientific Council of the French National Agency for Research on AIDS and Viral Hepatitis (ANRS), the Scientific Advisory Committees of the South African AIDS Vaccine Initiative (SAVI), and Clinical Trials Committee of the International AIDS Vaccine Initiative (IAVI).

The author of over 200 peer-reviewed articles, Dr. Schechter is the Epidemiology Section Editor, AIDS Research and Human Retroviruses Journal. His primary research interest is preventing and treating HIV/AIDS in different settings.

Dr. Schechter earned his M.D. at the Federal University of Rio de Janeiro and his PhD at the London School of Hygiene & Tropical Medicine, University of London. He was a Research Associate at the Rockefeller University, New York, and a Research Assistant Professor at New York University School of Medicine.

Potential conflict of interest:
 Gilead Sciences, GSK, Merck, ViiV



INVITED SPEAKER
FRANÇOIS VENTER,
MD, FCP, PhD

Ezintsha, University of the Witwatersrand, South Africa

Professor WD François Venter, MD, FCP, PhD is the Divisional Director of Ezintsha at the University of the Witwatersrand, Johannesburg, where he received most of his training.

He has an active interest in public sector access to HIV services, and his work involves health systems research that directly translates into national programmes, most recently involving dolutegravir and TAF. He leads multiple antiretroviral treatment optimisation studies and is currently working on new first and second-line antiretroviral options, patient linkage-to-care interventions, and self-testing projects. He has led large PEPFAR-funded HIV programmes in South Africa, focusing on different populations such as men, women, children, young people, truckers, sex workers and LGBTI.

For the last 20 years, he has been an advisor to bodies such as the South African government, Southern African HIV Clinicians Society, UNAIDS, and WHO, including contributing to international, regional, and national HIV guidelines. He has been involved in several human rights cases involving HIV within the Southern African region and has an active interest in medical ethics.

Potential conflict of interest:
 Bill and Melinda Gates Foundation, SA Medical Research Council, National Institutes for Health, AIDS Fonds, Unitaids, Foundation for Innovative New Diagnostics, Children’s Investment Fund Foundation, USAID, ViiV Healthcare, Gilead Sciences, Mylan, Merck, Adcock-Ingram, Aspen, Abbott, Roche, J&J, Sanofi, Virology Education



ORGANIZING COMMITTEE

MITCHELL WARREN

AVAC,
United States

Since 2004, Mitchell Warren has been Executive Director of AVAC, an international non-governmental organization that uses education, policy analysis, advocacy, communications and a network of global collaborations to accelerate the ethical development and global delivery of new and emerging HIV prevention options.

Previously, he served as Senior Director for Vaccine Preparedness at the International AIDS Vaccine Initiative (IAVI) focusing on increasing community understanding and national involvement in AIDS vaccine development; Vice President of International Affairs for The Female Health Company (FHC), manufacturer of the female condom, where he directed efforts to design and implement reproductive health programs and led global advocacy efforts for female-initiated prevention methods; and six years at Population Services International (PSI) designing and implementing social marketing, communications and health promotion activities, including five years running PSI's project in South Africa.

Warren is president of the TB Alliance Stakeholders Association; member of the President's Emergency Plan for AIDS Relief (PEPFAR) Scientific Advisory Board (SAB); and board member of the Towards an HIV Cure Initiative of the International AIDS Society (IAS). He is past president of the Global HIV Vaccine Enterprise. In 2013, he helped establish the biennial HIV Research for Prevention conference and is one of the co-chairs for R4P 2021. Warren has degrees in English and History from the University of Wisconsin-Madison and studied health policy at the Johns Hopkins University School of Hygiene and Public Health.

No potential conflict of interest



INDEPENDENT EDUCATIONAL GRANT



This educational activity is partially supported by an independent educational grant from MSD. MSD is not involved in the development of content or the selection of faculty for this educational activity.

ENDORSERS





We are pleased to announce that the **2nd HIV Prevention Review Meeting** will be held virtually on 30-31 March 2022.

The registration fee is waived for the following participants: Healthcare Professionals (HCPs), NGO Representatives, Advocates, Community Representatives, and Policymakers / Government Representatives. HCPs are defined as professionals that provide any type of health care service to patients living with HIV or other diseases.

Fees apply to representatives from industry, medical education providers, investment companies, and others not listed above.

We look forward to seeing you online again!

Read more here: www.academicmedicaleducation.com/meeting/hiv-prevention-review-meeting-2022



